文献速递中毒与环境急症消化、代谢与肾脏急症

2014年美国缉毒局对氢可酮产品更严格的附表规定对阿片类药物处方率的影响

The effect of a more strict 2014 DEA schedule designation for hydrocodone products on opioid prescription rates in the United States.
PubMed 文献 · Clin Toxicol (Phila) · 2019-02-21
一句话结论2014年缉毒局将氢可酮复方产品从附表III移至附表II后,美国多个州阿片类药物总处方量未实质改变,医生以曲马多替代氢可酮。

该研究纵向分析美国10个人口最多的州,从各州开始收集阿片类药物处方数据至2016年底,评估2014年10月6日缉毒局将氢可酮复方产品从附表III移至附表II的政策效果。结果显示,加州、佛罗里达州、密歇根州和纽约州每年每100人阿片类药物总处方量未实质改变;氢可酮复方产品处方率下降(加州43.2降至35.0;密歇根州66.8降至55.6;纽约州20.8降至15.1),但被曲马多(加州0.2升至9.9;密歇根州0.1升至17.3;纽约州0.0升至7.6)和羟考酮(加州8.7升至9.7;密歇根州10.3升至11.9;纽约州18.1升至18.8)处方率上升所抵消。其余6州无可行机制评估全州阿片类药物处方总量、常规清除收集数据或仅在研究后期建立报告机制。作者认为,需要替代方法来降低美国阿片类药物总处方率,且各州缺乏标准化处方报告使详细分析困难。

要点

  • 2014年10月6日缉毒局将氢可酮复方产品从附表III移至附表II后,加州、佛罗里达州、密歇根州和纽约州每年每100人阿片类药物总处方量未实质改变。
  • 氢可酮复方产品处方率下降(加州43.2降至35.0;密歇根州66.8降至55.6;纽约州20.8降至15.1),但被曲马多(加州0.2升至9.9;密歇根州0.1升至17.3;纽约州0.0升至7.6)和羟考酮(加州8.7升至9.7;密歇根州10.3升至11.9;纽约州18.1升至18.8)处方率上升所抵消。
  • 其余6个评估州无可行机制评估全州阿片类药物处方总量、常规清除收集数据或仅在研究后期建立报告机制。
  • 作者认为,氢可酮被类似药物替代提示需要替代方法来降低美国阿片类药物总处方率。
  • 作者指出,当前各州缺乏标准化处方报告使详细阿片类药物处方分析困难,不足以指导政策或监测政策变化的影响。

适用人群与场景

  • 美国10个人口最多的州,从各州开始收集阿片类药物处方数据至2016年底。

研究设计与关键结果

  • 研究类型为纵向分析,评估2014年10月6日缉毒局将氢可酮复方产品从附表III移至附表II的政策暴露。
  • 加州、佛罗里达州、密歇根州和纽约州每年每100人阿片类药物总处方量未实质改变。
  • 氢可酮复方产品处方率下降:加州43.2降至35.0;密歇根州66.8降至55.6;纽约州20.8降至15.1。
  • 曲马多处方率上升:加州0.2升至9.9;密歇根州0.1升至17.3;纽约州0.0升至7.6。
  • 羟考酮处方率上升:加州8.7升至9.7;密歇根州10.3升至11.9;纽约州18.1升至18.8。
  • 其余6个评估州无可行机制评估全州阿片类药物处方总量、常规清除收集数据或仅在研究后期建立报告机制。

证据类型、等级与局限

  • 证据类型:纵向分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,氢可酮被曲马多替代提示需要替代方法来降低美国阿片类药物总处方率。
  • 作者指出,当前各州缺乏标准化处方报告使详细阿片类药物处方分析困难,不足以指导政策或监测政策变化的影响。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

Background: From 1999 to 2010, the annual number of US deaths due to opioid overdose increased about 400% as the number of opioids prescribed yearly also increased by approximately 400%. Over this period, hydrocodone combination products drove the opioid epidemic, as they became the most frequently prescribed medication in the United States. Our objective was to determine if the Drug Enforcement Administration's (DEA) 2014 policy change - which made it more difficult to prescribe hydrocodone combination products by moving them from Schedule III to Schedule II - reduced the total amount of opioid prescriptions as intended. Methods: We conducted a longitudinal analysis of the 10 most populous US states, beginning at the time each state began collecting data on opioid prescribing, and concluding at the end of 2016. The exposure was the DEA-mandated October 6, 2014 hydrocodone combination product schedule change. Results: After the DEA's schedule change for hydrocodone combination products, the total number of opioids prescribed each year per 100 people did not substantially change in California, Florida, Michigan, or New York. Although prescription rates dropped for hydrocodone combination products (CA: 43.2, 35.0; MI: 66.8, 55.6; NY: 20.8, 15.1), the reduction was commensurately counteracted by increased rates for tramadol (CA: 0.2, 9.9; MI: 0.1, 17.3; NY: 0.0, 7.6) and oxycodone (CA: 8.7, 9.7; MI: 10.3, 11.9; NY: 18.1, 18.8). Surprisingly, the other 6 states assessed had no viable mechanism in place for assessing state-wide opioid prescription totals, routinely expunged collected data, or only instituted a reporting mechanism toward the end of our study. Conclusion: Total opioid prescriptions were relatively unchanged following the 2014 DEA-mandated schedule change, however, physicians did change their prescribing habits by substituting tramadol for hydrocodone combination products. This substitution of similar medications for hydrocodone suggests alternative approaches are needed to reduce total US opioid prescription rates. Additionally, the current lack of standardized prescription reporting by states makes detailed opioid prescription analysis alarmingly difficult and insufficient to guide policy or monitor the impact of policy changes.

来源:Clin Toxicol (Phila),查看原文。版权归原作者所有。

参考来源

  1. Harrison ML, Walsh TL. The effect of a more strict 2014 DEA schedule designation for hydrocodone products on opioid prescription rates in the United States. Clin Toxicol (Phila). 2019. PMID: 30789065. doi:10.1080/15563650.2019.1574976

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。